【摘要】目的探讨沉默交配型信息调节2 同系物-1(silent mating type information regulation 2 homolog 1，SIRT1)激活剂SRT1720 对重度失血性休克/复苏致大鼠急性肾损伤的治疗作用及机制。方法模型组、SIRT1 激活剂SRT1720 低、中、高剂量组(20、40、80mg/kg)建立重度失血性休克/复苏致大鼠急性肾损伤模型，建模成功后SIRT1激活剂SRT1720各剂量组给予相应药物，对照组、模型组给予等体积生理盐水；随后处死大鼠，测定肾/体比值、肌酐(SCr)、尿素氮(BUN)、肾脏SIRT1、信号转导转录激活剂-3
(signal transducers and activators of transcription factor 3，STAT3)mRNA 和蛋白水平、白细胞介素-2(IL-2)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平。结果与对照组比较，模型组肾/体比值、尿蛋白、SCr、BUN、IL-2、IL-6、TNF-α 升高(t 值分别为25.632、14.524、18.965、23.654、23.654、18.695、19.547，P 均＜0.001)；与模型组比较，SRT1720 各剂量组肾/体比值、尿蛋白、SCr、BUN、IL-2、IL-6、TNF- α 降低(t=21.526、19.654、23.654、25.148，32.654、19.654、21.548、25.965、24.967、28.741、30.365、31.654、23.654、18.475、26.548、29.512，30.248、24.659、24.965、22.698、26.985，P 均＜0.001)，且随着SRT1720 给药剂量的增加，肾/体比值、尿蛋白、SCr、BUN、IL-2、IL-6、TNF-α 逐渐降低，剂量-效应关系明显(t=38.632、19.625、25.847、27.489、26.954、29.547、32.685、34.489、32.362、24.548、29.654、28.415、35.957、32.548，P 均＜0.001)。与对照组比较，模型组肾SIRT1 mRNA 和蛋白水平降低(t=38.635、32.145，P 均＜0.001)，STAT3 mRNA 水平升高(t= 32.636、30.213, P 均＜0.001)；与模型组比较，SRT1720 各剂量组SIRT1 mRNA 和蛋白水平升高(t=18.965、23.147、28.476、30.216、23.654、28.471，P 均＜0.001)，STAT3 mRNA 和蛋白水平降低(t=22.654、25.489、29.548、33.265、41.326、29.635, P 均＜0.001)，且随着SRT1720 给药剂量增加，SIRT1 mRNA 和蛋白水平逐渐升高，STAT3 mRNA 和蛋白水平逐渐降低，剂量-效应关系明显(t=27.485、28.459、30.215、29.584、29.654、31.145、32.159、30.269，P 均＜0.001)。结论SIRT1 激活剂SRT1720 能减轻重度失血性休克/复苏致大鼠急性肾损伤；其机制与SIRT1激活剂SRT1720通过激活大鼠肾脏中SIRT1 表达，抑制STAT3 表达进而抑制炎性介质表达有关。
【Abstract】Objective To explore the effect and mechanism of SRT1720, the activator of silent mating type information regulation 2 homolog-1 (SIRT1), on severe hemorrhagic shock/resuscitation-induced acute kidney injury. Methods Rats were divided into control group, model group, SIRT1 activator SRT1720 low (20 mg· kg-1) group, medium (40 mg/kg) group, and high dose (80 mg/kg) group. Rats were then subjected to acute severe hemorrhagic shock/resuscitation to induced acute kidney injury. After establishment of the disease model, equal volume of normal saline was given to the rats in control and model group, and various doses of SRT1720 were given to the rats in SRT1720 low, medium and high groups. Rats were then sacrificed, and their kidney/ body ratio, serum creatinine (SCr), urea nitrogen (BUN), SIRT1 in kidney, signal transducer and activator of transcription 3 (STAT3) mRNA and protein, interleukin-2 (IL-2), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured. Results In model group, kidney/body ratio, urinary protein, SCr, BUN, IL- 2, IL- 6, and TNF- α increased as compared with those in control group (t=25.632, 14.524,18.965, 23.654, 23.654, 18.695 and 19.547 respectively, P＜0.001). In SRT1720 low, medium and high
groups, kidney/body ratio, urinary protein, SCr, BUN, IL- 2, IL- 6, and TNF-α decreased as compared with those in model group (t=21.526, 19.654, 23.654, 25.148, 32.654, 19.654 and 21.548, respectively, in SRT1720 low group; 25.965, 24.967, 28.741, 30.365, 31.654, 23.654 and 18.475, respectively, in SRT1720 medium group; 26.548, 29.512, 30.248, 24.659, 24.965, 22.698 and 26.985, respectively, in SRT1720 high group; P＜0.001); besides, SRT1720 dose and the lowering of the 7 biomarkers apparently have a dosEresponse relationship (t=38.632, 19.625, 25.847, 27.489, 26.954, 29.547 and 32.685, respectively, compared with those between SRT1720 low and medium groups; 34.489, 32.362, 24.548, 29.654, 28.415, 35.957 and 32.548, respectively,
compared with those between SRT1720 medium and high groups; P＜0.001). In model group, renal SIRT1 mRNA and protein decreased (t=38.635 and 32.145; P＜0.001) and STAT3 mRNA and protein increased (t=32.636 and 30.213, P＜0.001) as compared with those in control group. In SRT1720 low, medium and high groups, renal SIRT1 mRNA and protein increased (t=18.965 and 23.147 in SRT1720 low group; 28.476 and 30.216 in SRT1720 medium group; 23.654 and 28.471 in SRT1720 high group; P＜0.001) and STAT3 mRNA and protein decreased (t=22.654 and 25.489 in SRT1720 low group; 29.548 and 33.265 in
SRT1720 medium group; 41.326 and 29.635 in SRT1720 high group; P＜0.001) as compared with those in model group; additionally, SRT1720 dose and the changes of the 4 biomarkers apparently have a dosEresponse relationship (t=27.485, 28.459, 30.215 and 29.584, respectively, compared with those between SRT1720 low and medium groups; 29.654, 31.145, 32.159 and 30.269, respectively, compared with those between SRT1720 medium and high groups, P＜0.001). Conclusion The SIRT1 activator SRT1720 can alleviate acute renal injury induced by severe hemorrhagic shock/resuscitation in rats. The mechanisms may be that
SRT1720 activates the expression of SIRT1 and inhibits the expression of STAT3 in kidney, through which the expressions of inflammatory mediators are inhibited.
[1]Denk S, Weckbach S, Eisele P, et al. Role of Hemorrhagic Shock in Experimental Polytrauma.[J]. Shock, 2017, 49(b:154-163.
[2]Chang R, Holcomb JB. Optimal Fluid Therapy for Traumatic Hemorrhagic Shock[J]. Critical Care Clinics, 2017, 33(a:15-36.
[3]Jiao Y, Li Z, Loughran PA, et al. Frontline Science: Macrophage‐derived exosomes promote neutrophil necroptosis following hemorrhagic shock[J]. J Leukoc Biol, 2017, 103(b:175-183.
[4]Yamada N, Martin L B, Zechendorf E, et al. Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock[J]. Annals of Surgery, 2017, 268(b:348-356.
[5]Clendenen N, Nunns GR, Moore EE, et al. Hemorrhagic Shock and Tissue Injury Drive Distinct Plasma Metabolome Derangements in Swine.[J]. J Trauma Acute Care Surg, 2017, 83(d:635-642.
[6]Mvunta DH, Miyamoto T, Asaka R, et al. SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells 1[J]. Translational Oncology, 2017, 10(d:621-631.
[7]Hong, YANG, Zheng-tao, et al. SIRT1 plays a neuroprotective role in traumatic brain injury in rats via inhibiting the p38 MAPK pathway[J]. Acta Pharmacologica Sinica, 2017, 38(b:168-181.
[8] 李灵丰, 吴晓静, 孔倩, et al. 右美托咪定对胸部撞击-失血性休克复苏致大鼠急性肺损伤时NLRP3炎症小体的影响[J]. 中华麻醉学杂志, 2019, 39(6):754-757.
[9]Shah C A, Broglie L, Hu L, et al. Stat3 and CCAAT enhancer–binding protein β (C/ebpβ) activate Fanconi C gene transcription during emergency granulopoiesis[J]. Journal of Biological Chemistry, 2018, 293(1a:3937-3948.
[10]Ren Y, Du C, Shi Y, et al. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress.[J]. International Journal of Molecular Medicine, 2017, 39(5):1317-1324.
[11]Nguyen LT, Chen H, Mak C, et al. SRT1720 attenuates obesity and insulin resistance but not liver damage in the offspring due to maternal and postnatal high-fat diet consumption[J]. Am J Physiol Endocrinol Metab, 2018, 315(b:E196-E203.
[12]Liu X, Hu D, Zeng Z, et al. SRT1720 promotes survival of aged human mesenchymal stem cells via FAIM: a pharmacological strategy to improve stem cell-based therapy for rat myocardial infarction[J]. Cell Death & Disease, 2017, 8(d:e2731.
[13]Fatehi D, Soltani A, Ghatrehsamani M. STR1720, a potential sensitizer for radiotherapy and cytotoxicity effects of NVB-BEZ235 in metastatic breast cancer cells[J]. Pathology Research & Practice, 2018, 214(6):889-895.
[14]Li D, Wang X, Huang Q, et al. Cardioprotection of CAPE- o NO 2 against myocardial ischemia/reperfusion induced ROS generation via regulating the SIRT1/eNOS/NF-κB pathway in vivo and in vitro[J]. Redox Biology, 2018, 15:62-73.
[15]Chen X, Chen C, Fan S, et al. Omega-3 polyunsaturated fatty acid attenuates the inflammatory response by modulating microglia polarization through SIRT1-mediated deacetylation of the HMGB1/NF-κB pathway following experimental traumatic brain injury.[J]. Journal of Neuroinflammation, 2018, 15(a:116.
[16]Guan Y, Rao Z, Chen C. miR-30a suppresses lung cancer progression by targeting SIRT1[J]. Oncotarget, 2018, 9(d:4924-4934.
[17]Mahony R, Gargan S, Roberts K L, et al. A novel anti-viral role for STAT3 in IFN-α signalling responses[J]. Cellular & Molecular Life Sciences, 2017, 74(9):1755-1764.
[18]Liao X H, Xiang Y, Yu C X, et al. STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells[J]. Oncotarget, 2017, 8(9):15763-15774.
